Methods of reducing apolipoprotein C-III
First Claim
1. A method of reducing an apolipoprotein C3 (APOC3 ) level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day, wherein the composition comprises less than about 1%, by weight of all fatty acids present, docosapentaenoic acid.
2 Assignments
0 Petitions
Accused Products
Abstract
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
399 Citations
20 Claims
- 1. A method of reducing an apolipoprotein C3 (APOC3 ) level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day, wherein the composition comprises less than about 1%, by weight of all fatty acids present, docosapentaenoic acid.
- 11. A method of reducing an apolipoprotein C3 (APOC3) level of a subject having fasting baseline triglycerides of at least about 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day, wherein the composition comprises less than about 1%, by weight of all fatty acids present, docosapentaenoic acid.
Specification